Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab

  • MIMURA Naoya
    Divison of Hematology-Oncology, Chiba Cancer Center
  • KOJIMA Hiroshige
    Department of Gastroenterology, NHO Chiba East Hospital
  • TSUJIMURA Hideki
    Divison of Hematology-Oncology, Chiba Cancer Center
  • ISE Mikiko
    Divison of Hematology-Oncology, Chiba Cancer Center
  • SAKAI Chikara
    Divison of Hematology-Oncology, Chiba Cancer Center
  • FUKAI Kenichi
    Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University
  • YOKOSUKA Osamu
    Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University
  • KUMAGAI Kyoya
    Divison of Hematology-Oncology, Chiba Cancer Center

Bibliographic Information

Other Title
  • リツキシマブ併用化学療法後のB型肝炎ウイルス再活性化への対策
  • リツキシマブ ヘイヨウ カガク リョウホウ ゴ ノ Bガタ カンエン ウイルス サイカッセイカ エ ノ タイサク

Search this article

Description

Reactivation of hepatitis B virus (HBV) has been recognized as one of the most serious complications in patients receiving chemotherapy with rituximab. From October 2007 to December 2008, rituximab was administered to 123 B-cell lymphoma patients in our institute. Four patients with positive hepatitis B surface antigen (HBsAg) received preemptive entecavir, and none of them developed HBV reactivation. For 26 patients whose hepatitis B surface antibody (HBsAb) and/or hepatitis B core antibody (HBcAb) were positive, HBV-DNA was monitored for one year after completion of chemotherapy. During this period, HBV reactivation was observed in two patients. Hepatitis was prevented in one patient by the administration of entecavir at the time HBV-DNA turns positive. Another developed de novo hepatitis B due to failure of monitoring. Preemptive entecavir for HBsAg positive patients and HBV-DNA monitoring for HBsAb and/or HBcAb positive patients seem to be effective.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 51 (3), 213-215, 2010

    The Japanese Society of Hematology

References(5)*help

See more

Details 詳細情報について

Report a problem

Back to top